Cargando…

Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy

Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, ha...

Descripción completa

Detalles Bibliográficos
Autor principal: Yamashita, Yoriko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412138/
https://www.ncbi.nlm.nih.gov/pubmed/25583423
http://dx.doi.org/10.1093/jjco/hyu221
_version_ 1782368614093946880
author Yamashita, Yoriko
author_facet Yamashita, Yoriko
author_sort Yamashita, Yoriko
collection PubMed
description Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, have been elucidated. In addition, an association between endometriosis and the tumor has also been a focus of research in recent years. The aim of this review is to discuss the specificity and importance of molecular changes and various intriguing points that are not solved until today. Finally, future aspects, including hopes for the development of novel therapies, are discussed.
format Online
Article
Text
id pubmed-4412138
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44121382015-04-29 Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy Yamashita, Yoriko Jpn J Clin Oncol Review Articles Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, have been elucidated. In addition, an association between endometriosis and the tumor has also been a focus of research in recent years. The aim of this review is to discuss the specificity and importance of molecular changes and various intriguing points that are not solved until today. Finally, future aspects, including hopes for the development of novel therapies, are discussed. Oxford University Press 2015-05 2015-01-12 /pmc/articles/PMC4412138/ /pubmed/25583423 http://dx.doi.org/10.1093/jjco/hyu221 Text en © The Author 2015. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review Articles
Yamashita, Yoriko
Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
title Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
title_full Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
title_fullStr Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
title_full_unstemmed Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
title_short Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
title_sort ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412138/
https://www.ncbi.nlm.nih.gov/pubmed/25583423
http://dx.doi.org/10.1093/jjco/hyu221
work_keys_str_mv AT yamashitayoriko ovariancancernewdevelopmentsinclearcellcarcinomaandhopesfortargetedtherapy